Jim Simons Nurix Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $56.7 Billion
- Q2 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 324,000 shares of NRIX stock, worth $7.02 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
324,000
Previous 179,300
80.7%
Holding current value
$7.02 Million
Previous $2.64 Million
156.49%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.3MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$148 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$95.9 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$86.5 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$84.1 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$78.6 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.02B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...